Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Lena Truong"'
Autor:
Hyun Lee, Tian Zhu, Kavankumar Patel, Yan-Yan Zhang, Lena Truong, Kirk E Hevener, Joseph L Gatuz, Gitanjali Subramanya, Hyun-Young Jeong, Susan L Uprichard, Michael E Johnson
Publikováno v:
PLoS ONE, Vol 8, Iss 10, p e75144 (2013)
Development of drug-resistant mutations has been a major problem with all currently developed Hepatitis C Virus (HCV) NS3/4A inhibitors, including the two FDA approved drugs, significantly reducing the efficacy of these inhibitors. The high incidence
Externí odkaz:
https://doaj.org/article/865643715fb8455293491e77012d45c1
The enoyl-ACP reductase (FabI) enzyme is a well validated target for anti-staphylococcal drug discovery and development. With the goal of finding alternate therapeutics for drug-resistant strains of Staphylococcus aureus, such as methicillin-resistan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b3b2fedbb083a0c5a5db66ff25b5174
Autor:
Joseph L. Gatuz, Michael E. Johnson, Shuyi Cao, Arun K. Ghosh, Kavankumar Patel, Kirk E. Hevener, Lena Truong, Hyun Lee
Publikováno v:
ChemMedChem
We have previously developed two potent chemical classes that inhibit the essential papain-like protease (PLpro) of severe acute respiratory syndrome coronavirus (SARS-CoV). In this study, we applied a novel approach to identify small fragments that
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d527f9edbd2039ff4b2fd7a63fd3ed9
https://doi.org/10.1002/cmdc.201300134
https://doi.org/10.1002/cmdc.201300134
Publikováno v:
Journal of Chemical Information and Modeling. 52:2245-2256
Drug discovery and design for inhibition of the Hepatitis C Virus (HCV) NS3/4A serine protease is a major challenge. The broad, shallow, and generally featureless nature of the active site makes it a difficult target for "hit" selection especially us
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f10da364ea234441fdcc0f70f674bfb
https://doi.org/10.1021/ci300177p
https://doi.org/10.1021/ci300177p
Publikováno v:
Analytical Biochemistry
High-throughput screening (HTS) of large compound libraries has become a commonly used method for the identification of drug leads, and nonphysiological reducing agents have been widely used for HTS. However, a comparison of the difference in the HTS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86c32b567b46d842f0509d2e34a0b61b
Autor:
Jinhua Song, Teuta Boci, Michael E. Johnson, Pin Chih Su, Tina Mistry, Kirk E. Hevener, Jiangping Deng, James L. Cook, Arun K. Ghosh, Shahila Mehboob, Libby Brubaker, Bernard D. Santarsiero, Lena Truong
Francisella tularensis, the causative agent of tularemia, presents a significant biological threat and is a Category A priority pathogen due to its potential for weaponization. The bacterial FASII pathway is a viable target for the development of nov
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e7efe24e3df6fe10243ce4b77a81ddb
https://europepmc.org/articles/PMC4348352/
https://europepmc.org/articles/PMC4348352/
Autor:
Hyun Lee, Debbie C. Mulhearn, Lena Truong, Jaime Torres, Joseph L. Gatuz, Anuradha Mittal, Kavankumar Patel, Michael E. Johnson
Publikováno v:
Bioorganic & Medicinal Chemistry
We have used a combination of virtual screening (VS) and high-throughput screening (HTS) techniques to identify novel, non-peptidic small molecule inhibitors against human SARS-CoV 3CLpro. A structure-based VS approach integrating docking and pharmac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0aaf004fd5919d655e4a3c97e1092983
https://pubmed.ncbi.nlm.nih.gov/24332657
https://pubmed.ncbi.nlm.nih.gov/24332657
Autor:
Hyunyoung Jeong, Yan-Yan Zhang, Lena Truong, Susan L. Uprichard, Tian Zhu, Gitanjali Subramanya, Michael E. Johnson, Kavankumar Patel, Joseph L. Gatuz, Hyun Lee, Kirk E. Hevener
Publikováno v:
PLoS ONE
PLoS ONE, Vol 8, Iss 10, p e75144 (2013)
PLoS ONE, Vol 8, Iss 10, p e75144 (2013)
Development of drug-resistant mutations has been a major problem with all currently developed Hepatitis C Virus (HCV) NS3/4A inhibitors, including the two FDA approved drugs, significantly reducing the efficacy of these inhibitors. The high incidence
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bdde005096241f5e2908d64b5edc9934
https://pubmed.ncbi.nlm.nih.gov/24130685
https://pubmed.ncbi.nlm.nih.gov/24130685